These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

221 related articles for article (PubMed ID: 8126147)

  • 1. Pronounced blood glucose-lowering effect of the antilipolytic drug acipimox in noninsulin-dependent diabetes mellitus patients during a 3-day intensified treatment period.
    Worm D; Henriksen JE; Vaag A; Thye-Rønn P; Melander A; Beck-Nielsen H
    J Clin Endocrinol Metab; 1994 Mar; 78(3):717-21. PubMed ID: 8126147
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Long-term effects of a sustained-release preparation of acipimox on dyslipidemia and glucose metabolism in non-insulin-dependent diabetes mellitus.
    Davoren PM; Kelly W; Gries FA; Hubinger A; Whately-Smith C; Alberti KG
    Metabolism; 1998 Mar; 47(3):250-6. PubMed ID: 9500558
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effect of the antilipolytic nicotinic acid analogue acipimox on whole-body and skeletal muscle glucose metabolism in patients with non-insulin-dependent diabetes mellitus.
    Vaag A; Skött P; Damsbo P; Gall MA; Richter EA; Beck-Nielsen H
    J Clin Invest; 1991 Oct; 88(4):1282-90. PubMed ID: 1918378
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Restoration of growth hormone (GH) response to GH-releasing hormone in elderly and obese subjects by acute pharmacological reduction of plasma free fatty acids.
    Pontiroli AE; Manzoni MF; Malighetti ME; Lanzi R
    J Clin Endocrinol Metab; 1996 Nov; 81(11):3998-4001. PubMed ID: 8923850
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Metabolic effects of suppression of nonesterified fatty acid levels with acipimox in obese NIDDM subjects.
    Fulcher GR; Walker M; Catalano C; Agius L; Alberti KG
    Diabetes; 1992 Nov; 41(11):1400-8. PubMed ID: 1397716
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effects of prolonged Acipimox treatment on glucose and lipid metabolism and on in vivo insulin sensitivity in patients with non-insulin dependent diabetes mellitus.
    Vaag AA; Beck-Nielsen H
    Acta Endocrinol (Copenh); 1992 Oct; 127(4):344-50. PubMed ID: 1449046
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Lowering fatty acids potentiates acute insulin response in first degree relatives of people with type II diabetes.
    Paolisso G; Tagliamonte MR; Rizzo MR; Gualdiero P; Saccomanno F; Gambardella A; Giugliano D; D'Onofrio F; Howard BV
    Diabetologia; 1998 Oct; 41(10):1127-32. PubMed ID: 9794097
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Different acute and chronic effects of acipimox treatment on glucose and lipid metabolism in patients with type 2 diabetes.
    Saloranta C; Groop L; Ekstrand A; Franssila-Kallunki A; Eriksson J; Taskinen MR
    Diabet Med; 1993 Dec; 10(10):950-7. PubMed ID: 8306591
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effect of a sustained reduction in plasma free fatty acid concentration on intramuscular long-chain fatty Acyl-CoAs and insulin action in type 2 diabetic patients.
    Bajaj M; Suraamornkul S; Romanelli A; Cline GW; Mandarino LJ; Shulman GI; DeFronzo RA
    Diabetes; 2005 Nov; 54(11):3148-53. PubMed ID: 16249438
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Metabolic consequences of sustained suppression of free fatty acids by acipimox in patients with NIDDM.
    Saloranta C; Taskinen MR; Widen E; Härkönen M; Melander A; Groop L
    Diabetes; 1993 Nov; 42(11):1559-66. PubMed ID: 8405695
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A double blind study of the effect of acipimox on serum lipids, blood glucose control and insulin action in non-obese patients with type 2 diabetes mellitus.
    Fulcher GR; Catalano C; Walker M; Farrer M; Thow J; Whately-Smith CR; Alberti KG
    Diabet Med; 1992 Dec; 9(10):908-14. PubMed ID: 1478035
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Short-term acipimox treatment is associated with decreased cardiac parasympathetic modulation.
    Vestergaard ET; Cichosz SL; Møller N; Jørgensen JOL; Fleischer J
    Br J Clin Pharmacol; 2017 Dec; 83(12):2671-2677. PubMed ID: 28736944
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Inhibition of the rise in FFA by Acipimox partially prevents GH-induced insulin resistance in GH-deficient adults.
    Segerlantz M; Bramnert M; Manhem P; Laurila E; Groop LC
    J Clin Endocrinol Metab; 2001 Dec; 86(12):5813-8. PubMed ID: 11739444
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The nicotinic acid analogue acipimox increases plasma leptin and decreases free fatty acids in type 2 diabetic patients.
    Worm D; Vinten J; Vaag A; Henriksen JE; Beck-Nielsen H
    Eur J Endocrinol; 2000 Sep; 143(3):389-95. PubMed ID: 11022182
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Inhibition of lipolysis decreases lipid oxidation and gluconeogenesis from lactate but not fasting hyperglycemia or total hepatic glucose production in NIDDM.
    Puhakainen I; Yki-Järvinen H
    Diabetes; 1993 Dec; 42(12):1694-9. PubMed ID: 8243814
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Plasma adiponectin is modestly decreased during 24-hour insulin infusion but not after inhibition of lipolysis by Acipimox.
    Dullaart RP; Riemens SC; Meinardi JR; Wolffenbuttel BH; Sluiter WJ
    Scand J Clin Lab Invest; 2005; 65(6):523-31. PubMed ID: 16179286
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Improvement of insulin sensitivity by metformin treatment does not lower blood pressure of nonobese insulin-resistant hypertensive patients with normal glucose tolerance.
    Dorella M; Giusto M; Da Tos V; Campagnolo M; Palatini P; Rossi G; Ceolotto G; Felice M; Semplicini A; Del Prato S
    J Clin Endocrinol Metab; 1996 Apr; 81(4):1568-74. PubMed ID: 8636369
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Acute inhibition of lipolysis does not affect postprandial suppression of endogenous glucose production.
    Carey PE; Gerrard J; Cline GW; Dalla Man C; English PT; Firbank MJ; Cobelli C; Taylor R
    Am J Physiol Endocrinol Metab; 2005 Dec; 289(6):E941-7. PubMed ID: 15998660
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Peripheral and hepatic insulin sensitivity in non-insulin-dependent diabetes mellitus: effect of nonesterified fatty acids.
    Walker M; Agius L; Orskov H; Alberti KG
    Metabolism; 1993 May; 42(5):601-8. PubMed ID: 8492715
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Combined metformin-sulfonylurea treatment of patients with noninsulin-dependent diabetes in fair to poor glycemic control.
    Reaven GM; Johnston P; Hollenbeck CB; Skowronski R; Zhang JC; Goldfine ID; Chen YD
    J Clin Endocrinol Metab; 1992 May; 74(5):1020-6. PubMed ID: 1569149
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.